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One Sentence Summary:  33 
Tetracyclines improve experimental filariasis lymphatic pathology by targeting multiple 34 
aspects of an interleukin-4 receptor type-2 inflammatory pathway of lymphangiogenesis in a 35 
preclinical filarial disease model. 36 
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Abstract 38 
Lymphatic filariasis is the major global cause of non-hereditary lymphedema. We demonstrate 39 
the filarial nematode, Brugia malayi, induces lymphatic remodelling and impaired lymphatic 40 
drainage following parasitism of limb lymphatics in a mouse model. Lymphatic insufficiency 41 
was associated with elevated circulating lymphangiogenic mediators, including vascular 42 
endothelial growth factor C. Lymphatic insufficiency was dependent on type-2 adaptive 43 
immunity, interleukin-4 receptor, recruitment of C-C chemokine receptor-2 monocytes and 44 
alternatively-activated macrophages with pro-lymphangiogenic phenotype. Oral treatments 45 
with second-generation tetracyclines improved lymphatic function, while other classes of 46 
antibiotic had no significant effect. Second-generation tetracyclines directly targeted lymphatic 47 
endothelial cell proliferation and modified type-2 pro-lymphangiogenic macrophage 48 
development. Doxycycline treatment impeded monocyte recruitment, inhibited polarisation of 49 
alternatively-activated macrophages and suppressed T cell adaptive immune responses 50 
following infection. Our results determine a mechanism-of-action for the anti-morbidity effects 51 
of doxycycline in filariasis and supports clinical evaluation of second-generation tetracyclines 52 
as affordable, safe therapeutics for lymphedemas of chronic inflammatory origin. 53 
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Introduction 60 
Lymphedema (LE) affects 200 million individuals worldwide (1).  LE is caused by disruption of 61 
normal lymphatic function whereby return drainage of fluid, proteins, fats and immune cells 62 
(lymph) is impaired (2). LE is either hereditary, caused by mutations in genes controlling 63 
lymphatic development, or non-hereditary, caused by infection, trauma or surgical removal of 64 
lymphatics to prevent cancer metastasis (2, 3). The major cause of secondary LE is lymphatic 65 
filariasis (LF), a neglected tropical disease infecting an estimated 67 million people with a 66 
further 890 million at risk (4).  Filarial LE causes life-long physical and associative mental 67 
disability (5), ranking LF as the 4th highest contributor to global disability adjusted life years. 68 
Tangible progress has been made in LF elimination via mass drug administration of anti-filarial 69 
drugs, effectively halving the number of active infections between 2000 and 2013 (4), whereas 70 
numbers of LE patients has remained static at 40 million over the same time-period. Current 71 
treatment for filarial LE is limited to ‘morbidity management and disability prevention’, which 72 
involves a package of hygiene measures and implementation of physiotherapy in the 73 
household (6). No chemotherapeutic interventions are indicated for filarial LE. However, 74 
antibiotics are recommended to treat secondary skin bacterial infections which can reduce the 75 
frequency of periodic inflammatory episodes, known as acute dermatolymphangioadenitis 76 
(ADLA), a form of cellulitis. In a recent placebo-controlled clinical trial, whilst both amoxicillin 77 
(the standard antibiotic treatment for ADLA) and doxycycline reduced the frequency of ADLA, 78 
doxycycline also showed surprising efficacy in reversing LE grade (7).  79 
Lymphatic remodelling is a hallmark of filarial LE, with clearly established evidence from in 80 
vitro (8, 9), in vivo (10–13) and clinical (14–16) studies. How lymphatic remodelling develops 81 
and its role in LF pathology is poorly understood. 82 
In this study, we develop a novel murine hind-limb model of filarial infection, utilising 83 
longitudinal intravital imaging to demonstrate filarial infective larvae induce rapid lymphatic 84 
alterations, associated with induction of lymphatic insufficiency. We demonstrate that early 85 
filarial lymphatic pathology is primarily host-immune driven, characterising an interleukin-4 86 
receptor (IL-4R) ‘type-2’ dependent axis involving recruitment of inflammatory monocytes and 87 
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alternatively-activated macrophages (AAMf) that promote the development of lymphatic 88 
disease. We demonstrate that second generation tetracyclines can target multiple aspects of 89 
this pathway to ameliorate lymphatic pathology.  90 
  91 
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Results 92 
Brugia malayi infection induces lymphatic remodelling and dysfunction 93 
We developed a murine lymphatic pathology model whereby C57BL/6J mice were 94 
administered with subcutaneous inoculations of B. malayi infective third stage larvae (BmL3) 95 
to the left hind-limb (Figure 1A). We confirmed filarial larvae established intra-lymphatic 96 
infections by imaging motile, fluorescently labelled BmL3 within GFP-tagged Prox-1+ collecting 97 
vessels (lymphangions) of the infected hind-limb (Figure 1B and Supplemental Movie 1). 98 
Motile BmL3 could be observed within superficial dermal lymphatics from 3 hours to 4 days 99 
post-infection. Near-infrared intravital indocyanine green (ICG) lymphography was undertaken 100 
to investigate the impact of B. malayi larval infection on lymphatic structure and function 101 
(Figure 1A, Supplemental Figure 1 and Supplemental File 1). Clinical ICG lymphography has 102 
characterised “splash”, “stardust” and “diffuse” dermal backflow patterns, and visualisation of 103 
tortuous collateral lymphatics, associated with onset of LE in patients (17). At two-weeks post-104 
B. malayi infection, we observed the presence of all three dermal backflow patterns and 105 
tortuous collateral lymphatic development (Figure 1C, Supplemental Figure 2A-B). By image 106 
analysis we determined BmL3-infected C57BL/6J mice displayed significant levels of 107 
lymphatic remodelling in dorsal, lateral and ventral aspects of the infected limb (Figure 1C-D). 108 
Remodelling was pronounced at sites proximal to initial invasion of the superficial lymphatics, 109 
although by this time-point there was no evidence of motile intra-lymphatic larvae. By epi-110 
fluorescent imaging, we could detect significant, mean two-fold dilations of Prox-1+ lymphatic 111 
vessels at two weeks-post infection (Figure 1E-F). By comparing ICG dermal backflow in 112 
infected and uninfected limbs, significant ICG retention was evident in the infected limbs, 113 
compared to sham-controls (Figure 1G). Further, in an Evan’s Blue (EB) dermal retention 114 
assay (Supplemental Figure 1) significant EB accumulation in the skin of BmL3 infected limbs 115 
was discerned (Figure 1H). Repeat experiments using BALB/c mice demonstrated that all 116 
aspects of lymphatic pathology were reproducible on this background strain, although to a 117 
generally lower degree of severity (Supplemental Figure 2).  118 
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Because inbred mice mount an effective adaptive immune response to control B. malayi 119 
infection before chronic adult intra-lymphatic filarial parasitism can establish (18), we next 120 
investigated if infection-induced lymphatic remodelling and dysfunction resolved post-121 
clearance of filarial infection. BmL3 infected mice imaged at 16 weeks post-infection retained 122 
backflow and tortuous lymphatic patterning, with no significant decline in lymphatic 123 
remodelling or levels of lymphatic insufficiency, compared to 2 weeks post-infection (Figure 124 
1C,I-J). At 16 weeks-post infection, there was no evidence of active intra-lymphatic adult 125 
parasitism or circulating microfilariae, indicating lymphatic pathology persists long-term after 126 
initial induction by filarial infection.  127 
To explore host molecular mechanisms mediating filarial lymphatic pathology, we compared 128 
circulating plasma concentrations of a focused array of angiogenic / lymphangiogenic factors 129 
between 14dpi BmL3 and sham infected cohorts. A milieu of lymphangiogenic factors were 130 
upregulated in BmL3 infected mice including: Vascular endothelial growth factor-C (VEGFC), 131 
soluble activin receptor like kinase-1 (sALK-1) and prolactin (Figure 2A-B). As VEGFC is a 132 
well characterised primary lymphangiogenic mediator (19), we investigated the impact of 133 
isolated VEGFC delivery to the hind-limb skin-draining lymph nodes (sdLN). 134 
We administered a VEGFC expressing adenoviral vector (adVEGFC) to increase local 135 
VEGFC signalling in the same anatomical areas exposed to BmL3 infection. AdVEGFC 136 
treated groups displayed significantly higher levels of both lymphatic remodelling and 137 
insufficiency, compared to both naïve and GFP expressing adenoviral vector (adGFP) treated 138 
control mice, with mid-dose adVEGFC administration recapitulating magnitudes of lymphatic 139 
remodelling and pathology comparable to 14d BmL3 infected mice (Supplemental Figure 3).  140 
Filarial lymphatic pathology is dependent on IL-4 receptor type-2 adaptive immune responses 141 
Previous clinical studies have demonstrated a link between symptomatic LF and enhanced 142 
parasite-specific host adaptive immune responses (20, 21). In mice, a polarised ‘type-2’ 143 
adaptive immune response coordinates effective eosinophilic-mediated immunity against 144 
larval-stage filariae (22). We investigated the role of adaptive immunity by comparing 145 
magnitudes of lymphatic remodelling and insufficiency between WT and Severe Combined 146 
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Immunodeficient (SCID) mice lacking functional B and T lymphocytes. BmL3-infected CB.17 147 
(BALB/c congenic) SCID mice displayed muted levels of lymphatic remodelling which were 148 
not significantly different compared to sham controls and significantly lower than 149 
corresponding BALB/c WT infections assessed at either 2- or 5-weeks post-infection (Figure 150 
3A-B). Concomitantly, no significant difference in lymphatic insufficiency was observed 151 
between sham and infected SCID mice, judged by either ICG or EB dermal backflow at 2-152 
weeks post-infection (Figure 3C-D). We then characterised the localised CD4+T cell adaptive 153 
immune response in sdLN and major afferent lymphatic collecting vessels proximal to filarial 154 
parasitized and remodelled lymphatic tissues, utilising intracellular cytokine flow cytometry 155 
(Supplemental Figure 4). Significant expansions of ‘type-2’ interleukin (IL)-4 and IL-13 156 
secreting CD4+ T-cells were observed in sdLN single cell suspensions derived from BmL3 157 
infected mice at 14 dpi and CD4+ secretion levels of the regulatory-type cytokine, IL-10, was 158 
also increased, whilst local secretion levels of the ‘type-1’ cytokine, inferferon-g, remained 159 
unaltered following infection (Figure 2E-F). Subsequently, we tested whether ablation of type-160 
2 immune signalling would impact on the severity of filarial lymphatic pathology, utilising IL-4 161 
receptor alpha (IL-4Ra) deficient mice, unable to respond to either IL-4 or IL-13. Following 162 
BmL3 infection, IL-4Rα knockout mice (IL-4Rα-/-), on either BALB/c or C57BL/6 backgrounds, 163 
exhibited significantly diminished lymphatic remodelling and lymphatic dysfunction (Figure 4A-164 
D). Levels of circulating lymphangiogenic mediators were also significantly abrogated in IL-165 
4Rα-/- BmL3 infected mice, notably VEGF-C and angiopoetin-2 (Figure 4E-F). This data 166 
indicates a functional role for IL-4R-dependent type-2 adaptive immune responses in the 167 
induction of early filarial lymphatic pathology. 168 
Pro-lymphangiogenic inflammatory monocytes and alternatively-activated macrophages are 169 
mediators of filarial lymphatic dysfunction  170 
We investigated the contribution of local cellular inflammatory responses in mediating filarial 171 
lymphatic pathology. By immunophenotyping the sdLN and major afferent lymphatic collecting 172 
vessels proximal to BmL3 inoculation sites, we determined significant expansions of 173 
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CD11b+Ly6C+CCR2+ ‘inflammatory’ monocyte and CD11b+F480+MHCII+ MФ populations 174 
(Figure 5A-B), significant eosinophilic and neutrophilic granulocyte recruitments and T and B 175 
lymphocyte proliferations (Supplemental Figure 5). In the absence of functional IL-4Rα 176 
signalling, a slight decrease in monocyte recruitment was observed and lymphatic-tissue MФ 177 
expansions were significantly impeded following filarial infection (Figure 5A-B). A significant, 178 
2-fold reduction in MФ expressing the tissue residency marker, Tim-4 (23), in filarial infected 179 
WT but not IL-4Ra-/- mice was apparent (Figure 5C-D), suggestive of IL-4R-dependent 180 
recruitment of monocyte-derived MФ within the expanded lymphatic-tissue MФ pool, post 181 
BmL3 infection. Filarial-infection expanded lymphatic-tissue MФ also displayed significantly 182 
increased expression of the AAMФ markers, RELM-α and CD206 (mannose receptor; a 183 
specific marker of alternative activation within monocyte-differentiated MФ in cardiac and 184 
hepatic tissues) (24, 25) (Figure 3C-D). AAMФ development post-filarial infection in proximal 185 
lymphatic tissues was completely abrogated in the absence of intact IL-4R signalling (Figure 186 
3C-D). AAMФ polarisation is a well characterised hallmark of filarial infection (26), and IL-4-187 
stimulated AAMs are important in mediating filarial expulsion by sustaining recruitment of 188 
eosinophils (22). Because Mf are potent cellular mediators of angiogenesis and 189 
lymphangiogenesis (27), we explored the lymphangiogenic phenotype of purified monocytes 190 
and macrophages from lymphatic tissues post-filarial infection. Cell-sorted 191 
CD11b+Ly6C+CCR2+ inflammatory monocytes secreted significantly higher concentrations of: 192 
prolactin, sALK-1, IL-6 and amphiregulin, while CD11b+F480+MHCII+ MФ secreted 193 
significantly higher levels of VEGF-C compared to sham-infected controls (Figure 3E). In a 194 
tandem approach, we examined the direct pro-lymphangiogenic potential of type-2 cytokine 195 
or filarial-stimulated human THP-1 monocyte-derived MФ. For this we developed a human 196 
dermal lymphatic endothelial cell (LEC) proliferation assay following co-culture with monocyte-197 
derived MФ macrophages pre-conditioned with recombinant (r)IFN-γ, rIL-4+rIL-13, live BmL3 198 
or BmL3 extract (BmL3E) (Figure 6A). rIL-4+rIL-13, live BmL3 and BmL3E conditioned 199 
macrophages mediated significant LEC proliferation compared with either LEC cells cultured 200 
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in basal media alone, or in the presence of naïve THP1 monocyte derived MФ (Figure 6B). 201 
Analysis of conditioned media from rIL-4+rIL-13 stimulated monocyte-derived MФ revealed 202 
significantly elevated levels of pro-lymphangiogenic mediators: VEGFA, Follistatin, and 203 
Human Growth Factor (HGF) (Figure 6C), while significantly elevated VEGFC and HGF were 204 
observed in BmL3E-pulsed MФ conditioned media (Figure 6D). This human co-culture system 205 
confirmed monocyte-derived MФ exposed to both a type-2 dominated (IL-4+IL-13) 206 
microenvironment and filarial-specific antigenic stimuli polarise toward a lymphangiogenic 207 
phenotype, capable of inducing the proliferation of LECs. 208 
To interrogate the functional role of pro-lymphangiogenic monocytes and monocyte-derived 209 
MФ recruited to the site of filarial-parasitised lymphatics, we blocked CCR2 monocyte 210 
recruitment following BmL3 infection by administration of an anti-CCR2 (α-CCR2) ablating 211 
antibody (28). In a complementary approach, we reduced total phagocyte cell populations, 212 
including monocytes and Mf, by local subcutaneous administration of clodronate-213 
encapsulated liposomes (CL) (Figure 7A). Confirming treatment efficacy, both α-CCR2 and 214 
CL treatments delivered to filarial infected mice successfully reduced circulating blood 215 
monocyte populations. Further, α-CCR2 significantly reduced lymphatic-associated monocyte 216 
populations following infection (Figure 7B-C). Following ablations of monocyte and total 217 
phagocyte populations, whilst remodelled lymphatics were still apparent, the magnitude of 218 
lymphatic insufficiency was significantly reduced, demonstrated by reduced backflow of ICG 219 
following α-CCR2 treatment (Figure 7F-G) and dermal retention of EB (Figure 7H) following 220 
both α-CCR2 and CL treatments. Additionally, dermal lymphatic vessel dilation was 221 
significantly reduced following both α-CCR2 and CL treatments (Figure 7I-J). These ablation 222 
experiments indicate a functional role for pro-lymphangiogenic monocyte populations, post-223 
recruitment from the blood to local parasitized lymphatics, in the development of filarial-224 
associated lymphatic dysfunction.  225 
Second generation tetracyclines target IL-4 receptor-dependent macrophage 226 
lymphangiogenesis to ameliorate filarial lymphatic pathology. 227 
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With previous work demonstrating anti-morbidity efficacy of the second generation 228 
tetracycline; doxycycline, in the treatment of filarial LE (7, 16, 29), we established whether our 229 
preclinical filarial-lymphatic pathology model was responsive to oral doxycycline intervention. 230 
After 14-days infection and co-treatment with a doxycycline regimen bioequivalent to human 231 
200mg daily oral dosing (30) (Figure 8A), mice exhibited significantly lower levels of both 232 
lymphatic remodelling (Figure 8B-C) and lymphatic insufficiency compared with infected and 233 
vehicle control animals (Figure 8D-E). We did not observe direct anti-filarial efficacy at these 234 
treatment dose ranges against B. malayi developing larvae up to 14 days, ruling out a direct 235 
anti-parasitic mode-of-action contributing toward reduced pathology (Supplemental Figure 6). 236 
Because the filarial endosymbiont, Wolbachia, is depleted by tetracyclines (30, 31) and can 237 
trigger innate inflammation via ligation of surface lipoproteins by toll-like receptor two and six 238 
heterodimers (TLR2/6) (32), we investigated whether initiation of lymphatic pathology was 239 
influenced by Wolbachia. In addition, using the related second-generation antibiotic, 240 
minocycline, and a selection of different classes of antibiotic, we tested whether suppression 241 
of lymphatic pathology was a phenomenon unique to the tetracycline class or could be 242 
mediated by other antibiotics with anti-Wolbachia and/or broad-spectrum antibacterial 243 
activities (Figure 9A). We selected high dose rifampicin as a broad-spectrum antibiotic with 244 
superior anti-Wolbachia activity compared to tetracyclines (33), as well as amoxicillin and 245 
chloramphenicol; both potent, broad-spectrum antibiotics lacking significant anti-Wolbachia 246 
activity (34). Similar to effects observed with doxycycline, minocycline, delivered at doses bio-247 
equivalent to 100mg human oral exposures (30), led to significantly improved severity of 248 
lymphatic remodelling and insufficiency (Figure 9B-D). Comparatively, none of the other 249 
administered broad-spectrum antibiotics: amoxicillin, chloramphenicol or rifampicin, had any 250 
significant effect on either lymphatic remodelling or insufficiency following filarial lymphatic 251 
infection (Figure 9B-D). Filarial-infected TLR-6 deficient mice displayed no significant 252 
difference in either magnitude of lymphatic remodelling or lymphatic insufficiency compared 253 
to WT controls (Figure 9E-G). Together, this data defines a specific anti-morbidity efficacy of 254 
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second generation tetracyclines in ameliorating filarial-induced lymphatic pathology, 255 
independent of general antibiotic or anti-Wolbachia specific modes-of-action. 256 
We tested which facets of the type-2 inflammatory lymphangiogenic pathway induced by 257 
filarial infection were targeted by tetracyclines. We first investigated whether doxycycline could 258 
directly affect lymphangiogenesis in vitro. Growth assays, utilising time-lapse microscopy to 259 
longitudinally quantify LEC or tissue-equivalent adult human dermal microvascular vascular 260 
endothelial cell (blood endothelial cell; BEC) proliferation over nine days were performed 261 
(Supplemental File 2). Treatment of LEC or BEC with 10-20µM doxycycline impeded 262 
proliferation in response to a VEGFA stimulus, in a dose dependent manner (Figure 10A-B; 263 
Supplemental File 2). Similar effects were obtained with BECs and LECs treated with 264 
minocycline (Supplemental Figure 7). We then treated monocyte-derived Mf with 10µM 265 
doxycycline simultaneously during stimulation with live BmL3, BmL3 with type-2 cytokines or 266 
BmL3 extract. Mf were washed before their transfer within trans-wells onto LEC cultures to 267 
remove drug (Figure 10C). Whilst rIL4+rIL13-, BmL3+rIL4+rIL13- and BmL3E-pulsed Mf 268 
mediated significant LEC proliferation, this affect was abolished by pre-treatment with 269 
doxycycline (Figure 10D). Addition of 10µM doxycycline to BmL3E-pulsed Mf and LEC co-270 
cultures also abrogated LEC proliferation (Figure 10E). No significant cytotoxicity was 271 
discerned when LEC or THP-1 Mf were exposed to 10-20µM doses of doxycycline and LEC 272 
cultures responded to VEGF proliferating stimulus following removal of drug (Supplemental 273 
Figure 8). These in vitro data indicate that second-generation tetracyclines reversibly suppress 274 
VEGF-mediated lymphangiogenesis and, independently, the development of pro-275 
lymphangiogenic monocyte-derived Mf following filarial and/or type-2 cytokine stimulations. 276 
Using the filarial lymphatic pathology mouse model, we immuno-phenotyped lymphatic-277 
associated myeloid cells from mice orally dosed with doxycycline compared with infection 278 
vehicle-dosed controls. Doxycycline treated mice displayed significantly impeded monocyte 279 
recruitment compared to infection controls whilst lymphatic-associated MФ populations failed 280 
to expand (Figure 11A). Eosinophil levels in lymphatic tissues were also significantly reduced 281 
 14 
in infected mice following doxycycline treatment (Figure 11A).  Doxycycline treatment also 282 
significantly blocked AAMf polarisation as measured by reduced populations of RELMα+ MФ 283 
(Figure 11B-C). We examined if this modified myeloid cell recruitment and reduced AAMf 284 
lymphangiogenic potential resulted in reduced local concentrations of the lymphangiogenic 285 
milieu. Ex vivo culture of single cell suspensions prepared from sdLN and adjacent lymphatic 286 
channels of filarial-infected mice treated with doxycycline demonstrated reductions in multiple 287 
lymphangiogenic secretions compared to infection controls (Figure 11D). Follistatin was 288 
significantly reduced, whilst VEGF-C secretions remained at sham-infection control levels 289 
(Figure 11E). We then examined whether the initial, predominant type-2 adaptive immune 290 
response important for mediating lymphatic pathology was perturbed by doxycycline. We 291 
assessed splenocyte recall assays to evaluate systemic immune responses. Doxycycline 292 
treatments modified numerous cytokines, compared to BmL3 infection alone (Figure 11F-G). 293 
Reductions in secretions of type-2 cytokines: IL-3, IL-4, IL-9 and IL-5 were observed post-294 
doxycycline treatment in infected mice. Additionally, modified systemic type-1 (IFNg) and type-295 
17 (IL-17) splenocyte secretions were recorded post-doxycycline treatment.  Further, general 296 
reductions in chemokine production, including those responsible for monocyte and 297 
macrophage activation (CXCL2, G-CSF), as well as the pro-lymphangiogenic growth factor, 298 
VEGF-A, were observed within splenocytes, post-doxycycline treatment (Supplemental Figure 299 
9). Therefore, second-generation tetracyclines target multiple aspects of the type-2 300 
inflammatory lymphangiogenic axis induced by filarial larval infection, as well as directly 301 
targeting lymphatic endothelial proliferation, to modify lymphatic filarial disease. 302 
  303 
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Discussion 304 
We reveal persistent lymphatic dilation, remodelling and dermal backflow patterns in mice that 305 
emulate clinical lymphatic remodelling in both filarial and non-filarial LE patients (14–17). 306 
Further, we record significant upregulation of the pro-lymphangiogenic circulating factors, 307 
Ang2, TNFa and VEGFC, which are clinical serological markers of filariasis infection and LE 308 
pathology (29, 35, 36). Thus, we conclude that our preclinical model is representative of early 309 
lymphatic pathological changes in filariasis patients and a useful tool to interrogate the 310 
pathophysiology and therapeutic targeting of filarial disease.  311 
Our model revealed that, surprisingly, abbreviated larval filarial infections, in as little as 6 days, 312 
could rapidly induce enduring lymphatic pathology without the necessity for establishment of 313 
chronic adult infections. It is currently not known whether such rapid pathology is evident in 314 
humans as markers of adult filarial infection are typically utilised as selection criteria for study. 315 
However, a recent investigation has defined via lymphoscintigraphy that lymphatic pathology 316 
is evident in children as young as five (37). Thus, we contend that frequent larval assaults 317 
transmitted by mosquito bites, that do not necessarily result in patent adult infections, may 318 
cause under-appreciated lymphatic pathology in LF endemic areas.  319 
Strain-dependent magnitude of lymphatic remodelling, whereby BALB/c mice exhibited 320 
reduced pathology compared with C57BL/6 mice, reflects the relative vigour of sterilising 321 
immunity against filarial infection between these two strains (38). Indeed, severity of LE in 322 
filariasis patients is associated with magnitude of CD4+ T cell immune responses to filarial 323 
antigen (20). In our model, local draining lymph node adaptive immune responses were 324 
polarised toward IL-4 and IL-13 CD4+ secretion, suggesting an important role for type-2 325 
sterilising immune responses in induction of lymphatic dysfunction. We have defined 326 
eosinophil coordinated type-2 immune responses are critical to prevent B. malayi larval 327 
survival (22, 39). Lymphatic remodelling and dysfunction were reduced in SCID mice following 328 
filarial infection, demonstrating a requirement for adaptive immunity to induce early lymphatic 329 
dysfunction.  330 
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A Limitation of our study was that whilst lymphatic pathology was rapidly induced, we did not 331 
observe overt LE in immuno-competent mice following a single infection event and up to 16 332 
weeks follow-up. Further, we used a single high dose infection (100 L3) whereas humans will 333 
be naturally exposed repetitively to low doses of typically <10 L3 in ‘trickle infections’. Whilst 334 
dilation of B. malayi adult parasitized lymphatics and LE formation has been documented in 335 
B. malayi susceptible T cell immune-deficient mice (11, 13), reactivation of adaptive immunity 336 
during chronic infection time-courses in aged mice was not scrutinised in these ‘leaky’ 337 
lymphopenic models. Indeed, experimental immune reconstitution triggers a destructive, 338 
fibrotic, peri-lymphangitis pathology with myeloid-rich infiltrates in infected lymphatics co-339 
incident with immune-killing of adult parasites (11). Further, in experimental infections of 340 
outbred feline and canine natural Brugia hosts, overt LE is associated with leukocytic intra-341 
lymphatic obstructive thrombi and exacerbated by bacterial or fungal secondary infections (40, 342 
41). In a susceptible ferret model of B. malayi infection, six trickle-dose inoculations over a 343 
ten-week period resulted in overt LE in one out of four animals tested (12). Thus, we suggest 344 
the immediate adaptive immune-dependent lymphatic pathology we detail is an early facet of 345 
a complex multi-factorial process, likely requiring several chronic infection events within the 346 
limb lymphatic network and prime-boosting of type-2 immunity to culminate in pronounced 347 
lymphedematous disease.  348 
In non-filarial LE models, CD4+ T cell depletion reduces lymphatic pathology, whilst specific 349 
neutralisation of type-2 cytokines, IL-4 and IL-13, ameliorates oedematous skin fibrosis (42, 350 
43). Confirming the importance of type-2 immunity in filarial lymphatic pathology, IL-4 receptor 351 
deficient mice did not develop significant remodelling and were protected from lymphatic 352 
dysfunction post-infection. IL-4R deficiency resulted in: reductions in multiple circulating 353 
lymphangiogenic factors, notably VEGFC and Ang2, reduced monocyte / Mf expansions 354 
within parasitized lymphatics and prevention of Mf alternative activation. We, and others, have 355 
previously described IL-4 receptor-dependent alternative activation of serous-cavity tissue Mf 356 
populations in the context of filarial infection (22, 44). In oncology, dysregulated, tumour-357 
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derived stimuli polarises monocytes and macrophages into “tumour-associated” phenotypes, 358 
possessing similarities to AAMf, and resulting in increased tumour angiogenesis and 359 
lymphangiogenesis (45). In clinical filariasis, circulating monocytes with features of alternative 360 
activation have also been detected (46). We determined that lymphatic-associated monocytes 361 
and AAMf from parasitized tissues produced elevated VEGFC, sALK-1 and prolactin, the 362 
three most upregulated pro-lymphangiogenic molecules in circulation following filarial 363 
infection, demonstrating this cell lineage are cellular sources of lymphangiogenic mediators at 364 
the site of filarial lymphatic pathology. Clinically, it has been shown that circulating blood 365 
mononuclear cells derived from filarial LE patients also demonstrate heightened VEGFA/C 366 
production upon ex vivo stimulations with either TLR or filarial antigens (47).  367 
By serial depletion of CCR2+ monocytes or total phagocytes in vivo, we confirmed temporal 368 
monocyte deficiency and impaired lymphatic recruitment alleviated lymphatic dysfunction and 369 
reduced lymphatic dilation. Similarly, CCR2 monocyte recruitment has been demonstrated to 370 
mediate intestinal inflammatory lymphangiogenesis (48), whereas monocyte CD36 blockade 371 
prevents corneal lymphangiogenesis (49) suggesting a common mechanism in inflammatory 372 
lymphangiogenesis induction. We hypothesise that the gross local dilation in parasitized skin 373 
lymphangions impairs trafficking of solutes from proximal interstitial spaces during type-2 374 
filarial inflammation. Lymphangion lumen dilation to the point of valve dysfunction has been 375 
proposed as a mechanism for lymphostasis in post-surgical LE (50). In filarial hydrocele 376 
pathology, gross ‘honeycomb’ dilation of the supra-testicular lymphatics correlates with 377 
circulating VEGFA levels (15). As VEGFA and VEGFC both activate lymphatic endothelium 378 
via VEGFR1/2 and VEGFR3, respectively, our data supports VEGFA/C-specific activation of 379 
the superficial lymphatics during filarial type-2 inflammation, delivered by recruited CCR2+ 380 
monocytes and their subsequent differentiation into AAMf. However, we also identified 381 
circulating and monocyte-specific production of other lymphangiogenic factors, namely sALK-382 
1 and prolactin, whilst another lymphangiogenic factor, Ang-2, which was IL-4R type-2 383 
dependent in circulation, was not produced by the monocyte/macrophage lineage within 384 
 18 
parasitized lymphatics. This suggests additional lymphangiogenic factors contribute to 385 
remodelling events during initiation of type-2 filarial inflammation within skin-draining 386 
lymphatics. The relative functional roles of these multiple growth factors need investigating to 387 
determine whether targeted antiangiogenics may be of therapeutic benefit in filarial LE. 388 
In our human co-culture system, monocyte-differentiated Mf polarised with type-2 cytokines, 389 
resulted in a Mf phenotype able to induce LEC proliferation. However, live filarial larvae or 390 
their products could also induce a Mf phenotype without additional type-2 cytokine ‘help’. 391 
Type-2 or filarial polarised monocyte-derived Mf in vitro produced increased secretions of 392 
VEGFA/C, follistatin and HGF. Filarial-specific activation of human CD14+ monocytes has 393 
been prior demonstrated to induce pro-lymphangiogenic VEGFA secretions(9) . Thus, local 394 
‘patrolling’ CD14+ monocyte populations in the lymphatics may also be able to facilitate 395 
localised lymphatic dilations in the immediate vicinity of invading larvae in response to larval 396 
secretions. This may facilitate larval migrations through lymphatics and would occur prior to 397 
initiation of type-2 immunity, resulting in the recruitment of inflammatory monocytes, their 398 
differentiation into alternatively-activated Mf and resultant augmented and widespread 399 
lymphatic pathology. 400 
Prior clinical research has promoted an anti-pathology role of six-week 200mg/day 401 
doxycycline treatment in ameliorating filarial LE pathologies (7, 16, 29, 51). Reduced 402 
circulating VEGFA/C were observed in these studies, strengthening a hypothesis that chronic 403 
lymphatic remodelling supports development and maintenance of filarial LE (7, 16, 29). The 404 
mechanism by which doxycycline mediates anti-morbidity effects in filariasis is difficult to 405 
determine in the clinic, due to its curative activity via targeting filarial Wolbachia (52), and its 406 
broad-spectrum antibiotic properties which reduce secondary skin bacterial infections and 407 
cellulitis complications (53). Further, Wolbachia can directly activate classical inflammatory 408 
processes upon liberation from filarial tissues (32) and have been identified as mediators of 409 
systemic adverse reactions in LF patients post-filaricidal treatment (54, 55). Therefore, 410 
Wolbachia may contribute to filarial LE via triggering classical inflammation (56) and 411 
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doxycycline may prevent this disease pathway. Upon characterising a type-2 inflammatory 412 
response causal in inducing filarial lymphatic pathology, we exploited our model systems to 413 
investigate the mode-of-action by which second-generation tetracyclines ameliorate filarial 414 
lymphatic disease. First, we established both doxycycline and the related second-generation 415 
tetracycline, minocycline, are directly anti-lymphangiogenic, blocking LEC proliferation to 416 
VEGF stimuli. These data confirm earlier reports that doxycycline directly modifies VEGFC-417 
induced LEC proliferation by interrupting phosphorylation of phosphoinositide 3 kinase (PI3K), 418 
alpha-serine/threonine protein kinase (AKT1) and endothelial nitric oxide synthase (eNOS) 419 
signalling (57). We also determined the suppressive effect of doxycycline extends to inhibiting 420 
LEC proliferation mediated by IL-4/13 or filarial-conditioned pro-angiogenic Mf. The anti-421 
angiogenic pharmacological activity of doxycycline or minocycline achieved in vitro, at 422 
between 10-20 µM, was at or slightly higher than typical clinical peak-plasma concentrations. 423 
However, concentrations of doxycycline, following 14-days dosing in the skin, are known to 424 
accumulate three-fold more than measured in circulation (58). This suggests our effective 425 
dose levels reflect local concentrations experienced within and surrounding superficial 426 
lymphatics.  427 
Anti-lymphangiogenic activities of doxycycline and minocycline were reproducible in vivo, 428 
whereby oral dosing mice with human bioequivalent regimens (30), significantly reduced 429 
magnitude of lymphatic remodelling and dysfunction induced by filarial infection. We 430 
determined this anti-pathology mechanism was tetracycline-specific and unrelated to broad-431 
spectrum antibiotic or anti-Wolbachia efficacies. Lack of evidence for Wolbachia in lymphatic 432 
pathology induction in our larval model probably reflects low Wolbachia titres in infectious 433 
stage B. malayi and does not necessarily preclude a role for higher titres of Wolbachia, 434 
liberated upon death of more mature filariae in parasitized lymphatics, augmenting LE 435 
pathology development in vivo. The skewed, local type-2 inflammation observed in our mouse 436 
model also reflects low Wolbachia exposure during initial immune priming, as we previously 437 
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demonstrated type-2 T cell polarisation by filarial extract becomes modified toward a mixed 438 
type-1 and type-2 T cell response by relative abundance of Wolbachia products (32).  439 
Doxycycline modified the type-2 recruited monocyte / AAMf pathway of lymphatic pathology 440 
at multiple points in vivo. Thus, we demonstrate that doxycycline has wide-ranging 441 
immunosuppressive and anti-inflammatory activities in modulating filarial-induced type-2 442 
inflammatory lymphangiogenesis. As doxycycline directly perturbed pro-lymphangiogenic Mf 443 
in response to type-2 or filarial-specific stimuli in vitro, this provides evidence of a specific 444 
targeted effect at the level of Mf. Doxycycline has previously shown to suppress IL-4/13 445 
dependent alternative-activation of monocyte-derived Mf, with concomitant impairment in Mf-446 
induced angiogenesis (59). The likely multi-faceted mechanisms by which second generation 447 
tetracyclines cause such wide-ranging anti-lymphangiogenic, anti-inflammatory and immuno-448 
suppressive effects on mammalian cells to stymy filarial type-2 lymphatic pathogenesis require 449 
detailed further investigations. An assumed mode of doxycycline-mediated anti-angiogenic 450 
activity in vivo has been via targeted inhibition of matrix metalloproteinases (MMPs) to prevent 451 
extra-cellular matrix degradation necessary for neovascularisation (60, 61). One alternative, 452 
emerging mechanism is that doxycycline suppresses mammalian mitochondrial protein 453 
synthesis, thus shifting cellular metabolism toward glycolysis and slowing cell proliferative rate 454 
(62). Finally, a recent study demonstrates that calcium signalling is relevant in VEGFA-induced 455 
angiogenesis (63). Because doxycycline is a known calcium ion chelator, anti-angiogenic and 456 
more wide-spread anti-proliferative effects of the drug could be mediated by attenuating 457 
multiple calcium-dependent, second messenger signalling pathways. Certainly, the T cell anti-458 
proliferative activity of doxycycline can be overcome by addition of exogenous calcium (64). 459 
As with current indications in the treatment of rheumatoid arthritis or rosacea (65), we identify 460 
that the mode-of-action of second-generation tetracyclines in mediating anti-pathology 461 
efficacy in filariasis is via immuno-suppressant / anti-inflammatory activities. However, akin to 462 
the dual mode-of-action considered important in the treatment of acnes (65) we do not 463 
discount that second-generation tetracyclines are also beneficial to filarial LE patients by 464 
 21 
resolving secondary bacterial infections, preventing ADLA episodes. Lipophilicity and dermal 465 
accumulation of second-generation tetracyclines may be important physiochemical features 466 
contributing to a ‘long-tail’ of anti-pathology activities in superficial lymphatics and local skin-467 
draining lymph nodes. Because minocycline is a more lipophilic antibiotic compared with 468 
doxycycline (30), it may be a clinically superior treatment for filarial LE, warranting comparative 469 
clinical assessment, while newly approved formulations of minocycline (66) for the treatment 470 
of skin complaints warrants clinical assessment of anti-pathology effects in filarial LE patients.  471 
Because “sterile” post-surgical LE has been clearly linked with inflammation and leukotriene 472 
production (67), doxycycline may be of therapeutic benefit in the treatment of non-filarial LE 473 
of inflammatory origin, especially where cellulitis complications contribute to disease aetiology.  474 
Potential limitations of the deployment of oral second-generation tetracyclines as anti-475 
morbidity therapy for filarial LE include the potential for gastrointestinal side effects, 476 
development of photosensitivity and contraindications during pregnancy and for young 477 
children. However, large scale implementation trials of doxycycline treatment as a cure for 478 
filariasis in over 13,000 African participants have determined >90% adherence to treatment 479 
and phase II trials have only reported infrequent and generally mild adverse effects during six-480 
week therapy (68). Large-scale, multi-centre trials are currently commencing to evaluate 481 
doxycycline as an anti-morbidity therapy for filarial LE (69).  Future clinical trials should also 482 
address dose duration and frequency, comparative efficacy of doxycycline versus minocycline 483 
and whether addition of affordable non-steroidal anti-inflammatory drugs, such as ketoprofen, 484 
which is currently undergoing clinical assessment for the treatment of post-surgery LE (70), 485 
may be of added benefit, including in contra-indicated groups. 486 
In conclusion, our preclinical research establishes the mode-of-action of second-generation 487 
tetracyclines as anti-morbidity drugs in the therapy of filarial LE. These findings support the 488 
onward clinical evaluation of these affordable, readily available and safe treatments for LE of 489 
filarial origin and potentially for other LE associated with chronic inflammation. 490 
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Materials and Methods 492 
Study design 493 
Group sizes of animal experiments were determined using appropriate sample size 494 
calculations to power a study >80%. Data was pooled from repeat experiments where done. 495 
Mice were randomized into infection / intervention groups by ID number. Dosing and 496 
interventions were done in a non-blinded manner. Image-based readouts were blinded prior 497 
to analysis.  498 
Experimental animals 499 
Laboratory animals were maintained in SPF facilities at The Biomedical Services Unit, 500 
University of Liverpool. Mongolian gerbils, BALB/c/C57BL/6J IL-4rα-/-, C57BL/6J Prox-1GFP, 501 
and C57BL/6J TLR-6-/- mice were bred in house. Mongolian gerbils were originally purchased 502 
from Charles River, Europe. BALB/c IL-4rα-/- mice were originally purchased from Jackson 503 
Laboratories, USA. C57BL/6J IL-4rα-/- mice were originally gifted by Dr Cecile Benezech, 504 
Edinburgh University. FVB/N-Crl:CD1(ICR) Prox-1GFP mice were provided by Professor 505 
Young-Kwon Hong, University of Southern California, before being back-crossed onto a 506 
C57BL/6J background for seven successive generations. C57BL/6J TLR-6-/- mice were 507 
originally gifted by Professor Shizuo Akira, Osaka University, Japan. Male BALB/c/C57BL/6J 508 
WT and CB.17 SCID mice were purchased from Charles River (Margate, UK). All mice were 509 
6-12wk at the start of procedures. Gerbils were infected between 8-12wk old. Males were used 510 
in this study.  511 
Parasite Life Cycle and Maintenance 512 
B. malayi life cycle was maintained in mosquitoes and Mongolian gerbils as previously 513 
described (31). Briefly, microfilariae (mf) from >12wk infected gerbils were collected via 514 
peritoneal catheterisation. Purified and enumerated mf were mixed with heparinised human 515 
blood to 15–20,000 mf/ml and artificial membrane feeder (Hemotek) fed to female Aedes 516 
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aegypti mosquitoes. Following 14d, infective B. malayi L3 larvae (BmL3) were collected from 517 
infected mosquitoes by crushing and Baermann’s filtration. 518 
Leg pathology model experimental infection 519 
Mice were inoculated with 100 BmL3 s.c., split between the top of left hind-foot and caudal to 520 
the left knee. Sham-infected mice received equal volumes of sterile RPMI1640.  521 
Intravital Near-Infrared (NIR) Imaging of lymphatics 522 
NIR imaging was adapted from techniques previously described (17). Briefly, anaesthetized 523 
mice were administered 20μl s.c. injections of 1mg/ml indocyanine green (ICG) (Sigma, Dorset 524 
UK) onto the top of left and right hind feet. Lymphatic drainage was monitored using a Photo 525 
Dynamic Eye (PDE) near infra-red (NIR) optical imaging device (Hamamatsu Photonics, 526 
Hertfordshire) to track NIR signal. Mice were imaged from 4 viewpoints: Dorsal, ventral, left 527 
and right. 720 x 480 at 60 fps movies (3 minutes per mouse) was recorded, using an EasyCap 528 
DC60 USB Video Capture Card Adapter (Softonic, Barcelona) that converted footage to 529 
ImageJ software (NIH, USA). 720x480 still images were used in downstream analysis. For 530 
more information see supplementary methods. 531 
Evan’s Blue dermal retention assay 532 
A modified Miles Assay was utilised whereby mice were administered s.c injections of 10µl 533 
1% Evan’s Blue (Sigma, Dorset UK) w/v in sterile dPBS (Sigma, UK) on top of the infected 534 
hind-foot. After 20min, mice were euthanized and left hind-leg skin excised between the knee 535 
and ankle joint, transferred to 1ml of dPBS (Sigma, UK) and incubated 20min. Absorbance 536 
was read at 620nm on a plate spectrometer (VarioSkan, Bio-Rad). 537 
Fluorescent microscopy  538 
Skin samples from C57BL/6J Prox-1GFP mice were dissected from areas of aberrant 539 
lymphatics (equivalent areas used in sham control mice). Lymphatic vessels were visualized 540 
using Prox-1GFP epifluorescence under a fluorescent stereo-dissecting microscope, eGFP filter 541 
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(Leica Microsystems, Milton Keynes). Between 15- 30 images were taken per mouse, blinded, 542 
and lymphatic channels measured for aperture in ImageJ (NIH, USA). All image 543 
measurements were pooled/mouse to calculate average lymphatic widths. 544 
BmL3 were washed before incubation with 50µM Alexa Fluor™ 546 NHS Ester (Succinimidyl 545 
Ester) (Thermofisher, UK) in Fluorobrite DMEM (Thermofisher, UK) for 2h. C57BL/6J Prox-546 
1GFP transgenic mice were injected with 400 fluorescent BmL3 as described above. After 3h 547 
and 1-6 dpi mice, areas of sub-cutaneous tissues where lymphatic remodeling occurs were 548 
imaged as above (DsRed and eGFP filters). 549 
Lymphoid-, lymphatic,- splenic- and blood-single cell preparations 550 
Cardiac blood was collected into heparinised tubes (Starstedt, Germany), centrifuged, plasma 551 
harvested and stored at -80ºC for downstream analysis. In blood immuno-phenotyping 552 
experiments, red blood cells were depleted using RBC lysis buffer (Biolegend, London), 553 
resuspended in dPBS (Sigma, Dorset) + 5% Foetal Bovine Serum (FBS) + 2mM EDTA (FACS 554 
buffer). Spleens or popliteal, iliac and sub-iliac lymph nodes with surrounding lymphatic 555 
collecting vessels were collected and a single cell suspension made by maceration through a 556 
40μm cell sieve (Sigma, Dorset). Resultant cell suspensions were centrifuged, re-suspended 557 
in RPMI1640 or FACS buffer and enumerated. 558 
Splenocyte and Lymph node cell recall assays 559 
LN cells and Splenocytes were plated at 2.5x105/well: splenocytes into previously coated 560 
1.25μg/ml anti-CD3 wells followed by the addition of 2μg/ml anti-CD28 (Biolegend, UK). LN 561 
cells with no ex vivo stimulation. All cells were incubated for 72 hours at 37°C 5% CO2 and 562 
subsequent supernatants frozen at -20°C.  563 
Multiplex Protein Array Analysis  564 
Multiplex immunoassays of 25 growth factors or 32 cytokine/chemokines (Mouse 565 
Angiogenesis/Growth Factor / Mouse Cytokine/Chemokine Magnetic Bead Panels, Merck) 566 
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were undertaken on plasma or re-stimulated splenocyte/lymph node cell cultures, following 567 
manufacturer’s protocol. Plates were read on Bioplex 200 system (Bio-Rad, Watford, UK) and 568 
data analysed using Luminex XPONENT software (Luminexcorp, Netherlands).  569 
Flow cytometry 570 
Single cell suspensions were FcR-blocked before staining with viability dye and specific 571 
fluorescently labelled antibodies (Table S1), as previously described (22). For intracellular 572 
cytokine experiments, sdLN suspensions were stimulated for 5h in cell stimulation cocktail 573 
(ebioscience Hatfield), followed by CD4 and intracellular cytokine staining. Data acquisition 574 
was undertaken on a BD LSRII Flow cytometer (BD Biosciences, Berkshire, UK). Data was 575 
analysed using FlowJo software (BD Biosciences, UK) (Figure S4).  576 
Fluorescent Antibody Cell Sorting (FACS) and cell secretion assays 577 
Following surface staining, cell populations (Figure S4) were sorted using a Becton Dickinson 578 
FACsAria II (BD Biosciences, Berkshire, UK) to ≥95% purity into ice cold dPBS (Sigma, 579 
Dorset) + 40% FBS Serum + 2mM EDTA. Purified B and T-cells were plated at 1x106 cells in 580 
250µl, while monocytes and macrophages were plated at 2.5x105 cells in 100µl into 96 well 581 
plates (Starlab, Milton Keynes). cells were incubated at 37ºC, 5% CO2 for 72h and collected 582 
supernatants frozen at -80ºC. 583 
Cell culture 584 
Primary (adult)– Human Dermal Lymphatic Microvascular Endothelial Cells (HMVEC-dLyAd: 585 
LECs) and Human Dermal Microvascular Endothelial Cells – (HMVEC-dAd; BECs) were 586 
purchased from Lonza (Slough) and passaged in Endothelial Growth Medium-2 Bullet kit 587 
(EGM-2) (Lonza, Slough). THP-1 monocytes (ECACC, Public Health England) were passaged 588 
in RPMI 1640 (Sigma, Dorset) supplemented with: 10% FBS (Sigma, Dorset), Penicillin / 589 
Streptomycin 100 I.U./mL (Sigma, Dorset) and Amphotericin B 2.5mg/L (Sigma, Dorset). All 590 
cells were maintained at 37ºC, 5% CO2. 591 
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Brugia malayi L3 larval extract (BmL3E) 592 
Batches of 1000-2000 B. malayi L3 were washed, re-suspended in E-toxate water (Sigma, 593 
Dorset) and extracts prepared as previously described (32), before storage at -20ºC. 594 
Macrophage/ LEC co-culture assay 595 
THP-1 monocytes were plated in 12-well trans-well inserts at 1x106 cells/well and 596 
differentiated into macrophages using 10ng/ml PMA (Sigma, Dorset) for 24h. Inserts were 597 
washed and stimulated with indicated combinations of: 10µg/ml BmL3E, 10 BmL3, 10ng/ml 598 
human rIL-4+rIL-13 or rIFNg (all Peprotech), 10µM Doxycycline or 20% EGM-2 : 80% 599 
endothelial basal media mix media only, for 48h. LECs were seeded separately on 12-well 600 
plates at 4x104 cells/well. Following 48h stimulation, inserts and LEC wells were washed 601 
combined and incubated for 72h at 37ºC, 5% CO2. LECs were enumerated following 602 
harvesting from plates by microscopy.  603 
LEC/BEC proliferation assays 604 
LEC/BEC were plated at 2x105cells/well into 96-well plates, stimulated with 2ng/ml VEGF165 605 
(VEGF) (Lonza, Slough) with or without 10 or 20μM of either doxycycline or minocycline 606 
(sigma, Dorset) and maintained at 37ºC, 5% CO2, for 10d. Proliferation was quantified 607 
longitudinally using the Incucyte live cell imaging platform with images taken hourly and results 608 
plotted as fold change from confluence at hour 0. 609 
CCR2 and clodronate liposome monocyte/macrophage depletion experiments 610 
Following infection, mice were administered either: 20μg MC-21 rat anti-mouse CCR2 611 
depleting antibody (Professor Matthias Mack, Rensburg University) (28)  i.p., daily, or 612 
2.5mg/ml clodronate liposome suspensions (Liposoma, Netherlands) s.c. at BmL3 infection 613 
sites every three days. Treatment was undertaken for 6d. 614 
Antibiotic screens 615 
Infected mice were randomized into groups and administered bi-daily: Doxycycline 40mg/kg, 616 
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Minocycline 25mg/kg, Amoxicillin 25mg/kg, Rifampicin 35mg/kg, Chloramphenicol 40mg/kg 617 
(all Sigma, UK) or ddH2O vehicle control via oral gavage for 14d.  618 
Statistical Analysis 619 
All continuous data was tested for normal distribution using the Kolmogorov-Smirnoff test. 620 
Where data was normally distributed, a two-tailed independent student’s t-test (2 groups) or 621 
One-way ANOVA with a Tukey’s post-hoc comparisons test (<2 groups) was used to test for 622 
significant differences. Where data was found to be not normally distributed, a log 623 
transformation was first attempted. If data remained non-parametric, a two-tailed Mann-624 
Whitney U test (2 groups) or Kruskal-Wallis with Dunn’s post-hoc multiple comparisons test 625 
(<2 groups) was utilised to test for significant differences between groups. The mean ± SEM 626 
are reported in all data unless otherwise stated. A P value <0.05 was considered significant. 627 
Significance is indicated as *=P<0.05, **=P<0.01, ***=P<0.001 ****=P<0.0001. 628 
Study approval 629 
All rodent experimental procedures were approved by the Animal Welfare Committee of 630 
University of Liverpool and The Animal Welfare and Ethics Review Board of Liverpool School 631 
of Tropical Medicine (LSTM) and carried out in accordance with The Use of Animals in 632 
Scientific Procedures Act (UK). 633 
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Figure 1 Filarial lymphatic infection induces persistent lymphatic pathology  817 
A) Schematic of hind-limb filarial infection model B) Representative images of in vitro (left 818 
panel) or intra-lymphatic AF456-labelled BmL3 larvae in C57BL/6J Prox-1GFP mice, 1dpi. C) 819 
Representative PDE intra-vital images of sham-infected and BmL3-infected C57BL/6J 820 
mice,14dpi D) Quantified aberrant lymphatics and E) Quantified hind-limb ICG dye retention 821 
from PDE imaging expressed as a ratio of fluorescence in the right ‘R’ (uninfected) : left ‘L’ 822 
(infected) hind-limb  (n=10 sham, n=8 BmL3). F) Representative epifluorescence micrographs 823 
of dermal lymphatics and G) average dermal lymphatic vessel aperture in Prox-1GFP mice 824 
14dpi, (n=3 Sham, n=4 BmL3). Scale bars=200µm. H) Evan’s Blue left hind-limb dermal 825 
retention (n=9 sham, n=8 BmL3). I) aberrant lymphatics and J) hind-limb ICG retention 826 
comparing 2- and 16-week old infections (n=15 sham, n=4 BmL3 2wpi, n=4 16 wpi). 827 
Histograms are mean±SEM (D-J). Data is pooled from 3 individual experiments (D-E), 2 828 
individual experiments (J) or 1 individual experiment (G, I-J). Significance is indicated as 829 
**=P<0.01, ***=P<0.001 derived from a one-way ANOVA with Tukey’s multiple comparisons 830 
post-hoc test (J) or two-tailed Student’s t-test (D-I). 831 
  832 
 38 
 833 
  834 
 39 
Figure 2 filarial infection induces increases in circulating lymphangiogenic molecules 835 
A) circulating levels of lymphangiogenic molecules. Heatmap plots median fold-change in 836 
analyte from sham-infected mouse group; red = fold-increase from sham-infected, blue = fold-837 
decrease (n=21 Sham; n=22 BmL3) B) circulating lymphangiogenic molecule concentrations 838 
from (A) for analytes achieving statistical significance. Histograms are medians. Data is pooled 839 
from 4 individual experiments. Significance is indicated as ***=P<0.001 derived from a Mann-840 
Whitney test. 841 
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Figure 3 filarial-associated lymphatic pathology is dependent on type-2 adaptive immunity 846 
A) Representative PDE intravital images and B) aberrant lymphatic quantification of BALB/c 847 
wild-type (WT) and SCID mice at 2- and 5wpi (n=8 WT sham, n=10 WT BmL3 +2wpi and 5wpi, 848 
n=5 SCID sham, n=4 SCID BmL3 2wpi, n=10 SCID BmL3 5wpi) C) hind-limb ICG dye retention 849 
and D) Evan’s Blue left hind-limb dermal retention in WT and SCID mice, 14dpi (n=7 WT sham, 850 
n=14 WT BmL3, n=5 SCID sham, n=4 SCID BmL3) E) Representative flow cytometry plots 851 
and F) quantified cytokine production within skin-draining lymph node CD4+ T-cells from 852 
C57BL/6J mice, 14dpi (n=12 Sham, n=13 BmL3). Data is cytokine expressing cells as a 853 
proportion of total CD4+ T cells. Histograms are mean±SEM. Data is pooled from 2 individual 854 
experiments (B,D,F) or a single experiment (D). Significance is indicated as *=P<0.05, 855 
**=P<0.01, ***=P<0.001, one-way ANOVA with Tukey’s multiple comparisons post-hoc test 856 
between marked groups. 857 
  858 




  862 
 43 
Figure 4 filarial-associated lymphatic pathology is dependent IL-4 receptor immune responses 863 
A) Representative images, B) quantified aberrant lymphatics and C) quantified hind-limb ICG 864 
dye retention in WT and IL-4Rα-/- BALB/c and C57BL/6J mice, 14dpi (n=20 BALB/c WT sham, 865 
n=21 BALB/c WT BmL3, n=8 IL-4Rα-/- BALB/c sham, n=15 IL-4Rα-/- BALB/c  BmL3, n=10 WT 866 
C57BL/6J  sham, n=10  WT C57BL/6J BmL3, n=5 IL-4Rα-/- sham and IL-4Rα-/- BmL3). D) 867 
Evan’s Blue left hind-limb dermal retention in WT and IL-4Ra-/- mice, 14dpi (n=8 BALB/c WT 868 
BmL3, n=5 IL-4Rα-/- BALB/c BmL3, n=8 WT C57BL/6J BmL3, n=5 IL-4Rα-/- sham & IL-4Rα-/- 869 
BmL3) E) Circulating levels of lymphangiogenic molecules between C57BL/6J WT and IL-870 
4Rα-/-  BmL3 infected mice, 14dpi. Heat-map plots median fold-change in analyte from sham-871 
infected mouse group; red = fold-increase from sham-infected, blue = fold-decrease (n=6 WT 872 
BmL3, n=7 IL-4Rα-/- BmL3). F) Plots of lymphangiogenic analytes achieving statistical 873 
significance. Histograms are mean±SEM. Data is pooled from 2-3 individual experiments; 874 
Significance is indicated as *=P<0.05, ***=P<0.001, one-way ANOVA with Tukey’s multiple 875 
comparisons post-hoc test (B-D) or two-tailed Student’s t-test between marked groups (F). 876 
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Figure 5 BmL3 infection drives lymphatic monocyte recruitment and expansion of alternatively 881 
activated, pro-lymphangiogenic macrophages  882 
A) Numbers of CD11b+Ly6C+CCR2+ inflammatory monocytes (n=16 Sham, n=14 WT BmL3, 883 
n=10 IL-4Rα-/- BmL3) or B) Cd11b+F480+MHCII+ MФ (n=6 Sham, n=10 WT BmL3; n=9 IL-4Rα-884 
/- BmL3) derived from sdLNs and major lymphatic channels in C57BL/6J mice, 14dpi. Data is 885 
total cell numbers or fold-change from relevant sham controls C) Representative flow plots of 886 
lymphatic MФ phenotyping in sham and BmL3 infected mice. Percentages are proportions of 887 
total CD11b+F480+MHCII+ MФ. D) CD206+, RELM-α+ and Tim-4+ MФ expression in WT and 888 
IL-4Rα-/- sham and BmL3 infected mice (n=9 WT Sham, n=9-17 WT BmL3, n=6 IL-4Rα-/- sham, 889 
n=5 IL-4Rα-/- BmL3). E) Significant changes in specific lymphangiogenic molecules secreted 890 
following 72-hour incubation ex vivo of FACS sorted lymphatic monocytes or MФ derived from 891 
sham or BmL3 infected mice. Secretion is normalised to analyte concentration/1x106 cells 892 
(n=4 Sham, n=5 BmL3). Data is pooled from (2-3 individual experiments). Histograms are 893 
mean ±SEM (A-D) or median (E). Significance is indicated as *=P<0.05, **=P<0.01, 894 
***=P<0.001, ns= not significant, derived from a two-tailed student t-test (A-B), a one-way 895 
ANOVA with Tukey’s multiple comparisons post-hoc test D) or a Mann Whitney Test (E). 896 
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Figure 6 Human monocyte-derived MФ conditioned with rIL-4 + rIL-13 and/or filarial L3 results 901 
in a lymphangiogenic phenotype that induces proliferation of lymphatic endothelium. 902 
A) Schematic of in vitro human dermal lymphatic endothelial cells (LEC) co-cultured with pre-903 
conditioned human monocyte-derived Mf. LEC proliferation was quantified 72-hour post 904 
addition of Mf co-cultures. B) LEC proliferation following monocyte derived MФ co-cultures 905 
conditioned with: recombinant IL-4 + IL-13 (rIL-4+rIL-13), live BmL3 (BmL3), BmL3 larval 906 
extract (BmL3E), rIL+4+rIL-13+BmL3 or unconditioned MФ, expressed as fold-changes from 907 
mean basal LEC enumerations C) Concentrations of lymphangiogenic molecules 72 hours 908 
following Mf culture in the absence or presence of rIL-4+rIL-13 or D) BmL3E (Mf+BmL3E), 909 
expressed as fold-changes from mean unstimulated Mf levels (M0). Histograms are mean 910 
±SEM. Data is pooled from 3 individual experiments (A-B) or a single experiment (C+D). 911 
Significance is indicated as *=P<0.05, **=P<0.01, ***=P<0.001, derived from a one-way 912 
ANOVA with Tukey’s multiple comparisons post-hoc test (B) or a two-tailed Student’s t-test 913 
between indicated groups (C+D).  914 
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Figure 7 Depletion of CCR2+ monocytes or phagocytes significantly ameliorates filarial-918 
induced lymphatic insufficiency. 919 
A) Schematic of CCR2+
 
monocyte and phagocyte depletion regimens in BmL3-infected 920 
C57BL/6J Prox-1GFP mice B) Representative flow cytometry plots from BmL3 infected, BmL3 921 
infected and either: treated with anti-CCR2 ablating antibody (BmL3+αCCR2) or clodronate 922 
(BmL3+CL), 2dpi. Percentages are CD11b+Ly6C+ cells as a proportion of live cells. C) 923 
CD11b+Ly6C+CCR2+ inflammatory monocytes isolated from hind limb lymphatic-tissues or D) 924 
blood, derived from sham, BmL3, BmL3+aCCR2 or BmL3+CL mice, 2dpi. Data in D) is 925 
reported as proportions of total white blood cells (WBC) (n=4 sham & BmL3, n=3 926 
BmL3+αCCR2 & BmL3+CL). E) Representative PDE images of sham, BmL3, BmL3+anti-927 
CCR2 and BmL3+CL mice, 6dpi. Yellow boxes highlight ICG retention F) aberrant lymphatics, 928 
G) hind-limb ICG retention and H) Evan’s Blue dermal retention in sham, BmL3 or 929 
BmL3+aCCR2 / +CL treated mice, 6dpi (n=5 Sham & BmL3, n=4 BmL3+αCCR2 & BmL3+CL). 930 
I) Representative epi-fluorescent images of lymphatic vessels and J) average lymphatic 931 
vessel aperture in sham, BmL3, BmL3+anti-CCR2 and BmL3+CL mice, 6dpi (n=5 Sham & 932 
BmL3, n=4 BmL3+αCCR2 & BmL3+CL). Scale bar 200µm. Data is from a single experiment. 933 
Histograms are mean ±SEM. Significance is indicated as *=P<0.05, **=P<0.01, ***=P<0.001, 934 
derived from a one-way ANOVA with Tukey’s multiple comparisons post-hoc test. 935 
  936 
 937 
  938 
 50 
  939 
 51 
Figure 8 Doxycycline administration significantly ameliorates filarial lymphatic pathology. 940 
A) Schematic of doxycycline intervention in BmL3-infected C57BL/6J mice. B) Representative 941 
images, C) aberrant lymphatics, D) hind-limb ICG dye retention in sham, BmL3+vehicle or 942 
BmL3+Doxycycline treated mice, 14dpi (n=13 Sham; n=23 BmL3+Vehicle, n=20 943 
BmL3+Doxycycline). Data plotted is % change normalised to mean values of the 944 
BmL3+vehicle control group in order to compare data pooled from independent experiments. 945 
E) Evan’s Blue dermal retention from left hind-limb skin (n=18 Sham; n=21 BmL3+Vehicle; 946 
n=11 BmL3+Doxycycline). Data is pooled from 3 individual experiments. Histograms are mean 947 
±SEM. Significance is indicated as *=P<0.05, **=P<0.01, ***=P<0.001, ns = not significant 948 
derived from a one-way ANOVA with Tukey’s multiple comparisons post-hoc test. 949 
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Figure 9 Doxycycline-mediated amelioration of filarial lymphatic pathology is independent of 953 
general antibiotic or anti-Wolbachia activity.  954 
A) Schematic for antibiotic screen and Toll-like receptor-6 knockout (TLR-6-/-) experiments in 955 
BmL3-infected C57BL/6J mice. B) Representative examples of PDE intravital imaging, C) 956 
aberrant lymphatics and D) ICG hind-limb retention in BmL3-infected mice treated bi-daily with 957 
vehicle (BmL3+Veh), minocycline (BmL3+Mino), amoxicillin (BmL3+Amox) chloramphenicol 958 
(BmL3+Chlor) or rifampicin (BmL3+Rif), 14dpi (n=23 BmL3+Veh; n=6 BmL3+Mino; n=8 959 
BmL3+Amox; n=6 BmL3+Chlor; n=5 BmL3+Rif). Data is % change normalised to mean of 960 
BmL3+Veh mice in order to compare data pooled from independent experiments E) 961 
Representative examples of PDE intravital imaging, F) aberrant lymphatics and G) ICG hind-962 
limb retention in WT or TLR-6-/- BmL3-infected mice or corresponding sham-infection 963 
controls,14dpi (n=5 WT & TLR-6-/- sham; n=4 WT+BmL3; n=6 TLR-6-/- +BmL3). Data is pooled 964 
from 2 individual experiments (BmL3+Amox in C-D) or a single experiment (BmL3+Mino, 965 
BmL3+Chlor, BmL3+Rif groups in C-D and F-G) Histograms are mean±SEM. Significance is 966 
indicated as *=P<0.05, **=P<0.01, ns= not significant derived from a one-way ANOVA with 967 
Tukey’s multiple comparisons post-hoc test. 968 
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Figure 10 Doxycycline inhibits LEC proliferation directly and via impairment of type-2 or filarial 972 
conditioned pro-lymphangiogenic Mf 973 
A) Blood Endothelial Cells (BEC) and LEC 9-day proliferation tracking following stimulation 974 
with 2ng/ml VEGF, with or without 10-20µM doxycycline. Data is fold-changes from initial 975 
BEC/LEC confluency. B) Representative images of BEC and LEC confluence at endpoint, 976 
scale bar=500µm. C) Schematic of Mf-LEC co-culture indicating where doxycycline was 977 
added. D) LEC enumeration following co-culture with MФ pre-conditioned with: rIL-4+rIL-13, 978 
rIL-4+rIL-13+BmL3 or BmL3 extract (BmL3E) with or without 10µM Doxycycline. E) LEC 979 
enumeration following co-culture with MФ pre-conditioned with BmL3E with/without 10µM 980 
Doxycycline. Histograms are mean ±SEM. Data is pooled from 2 individual experiments (D,E) 981 
or derived from a single experiment (A). Significance is indicated as *=P<0.05, ***=P<0.001, 982 
derived from a one-way ANOVA with Tukey’s multiple comparisons post-hoc test. 983 
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Figure 11 Doxycycline ameliorates filarial lymphatic pathology by modulation of IL-4R-dependent 986 
inflammatory lymphangiogenesis  987 
A) immune cell populations from sdLN and surrounding lymphatics from C57BL/6J sham- or BmL3-988 
infected mice treated with vehicle or 40mg/kg doxycycline bi-daily, 14dpi. B) Representative flow 989 
cytometry plots and C) MФ expression of Relm-a (n=6 Sham & BmL3+Veh; n=5 990 
BmL3+Doxycycline). Cells were gated on live CD11b+MHCII+F480+ cells. Data is Relm-α+ Mf as a 991 
proportion of total MФ. D) Proteomic array of lymphangiogenic molecules in 72h cell cultures 992 
derived from sdLN and lymphatic tissues, 14dpi. Heatmap orange and red depict increasing fold-993 
change compared with mean sham-infected mice E) lymphangiogenic molecules attaining 994 
statistical significance, data plotted per individual mouse (n=3 Sham, BmL3 & BmL3+Doxycycline) 995 
F). Proteomic array of cytokine levels in splenocyte cultures 72h post-polyclonal re-stimulation with 996 
aCD3/CD28. Heatmap orange and red depict increasing fold-change compared with mean sham-997 
infected measurement. G) Cytokine concentrations attaining statistical significance, grouped under 998 
type of adaptive immune response, data plotted per individual mouse (n=5 Sham, BmL3 & 999 
BmL3+Doxycycline). Histograms are mean ±SEM. Data is pooled 2 individual experiments (A,C) 1000 
or derived from a single experiment (E,G). Significance is indicated as *=P<0.05, **=P<0.01, 1001 
***=P<0.001, ns=not significant derived from a one-way ANOVA with Tukey’s multiple 1002 
comparisons post-hoc test. 1003 
 1004 
 1005 
